Lytton Leaves VC Firm for Biogen
Ryan McBride2/23/09
Michael Lytton has left his post as general partner at Boston venture firm Oxford Bioscience Partners to be executive vice president of business development at Cambridge, MA-based biotech powerhouse Biogen Idec (NASDAQ:BIIB), according to a press release. Lytton, a well-known venture capitalist who joined Oxford in 2001, will now be on the opposite side of deal talks from where he has sat as a board member with public and private life sciences startups in Oxford’s portfolio. A Biogen spokeswoman said that Lytton started work for the company today.













Pingback: Antibody Industry Week in Review | 2.27.09 — The Antibody Blog